Cyclerion Therapeutics Statistics
Total Valuation
CYCN has a market cap or net worth of $13.23 million. The enterprise value is $10.41 million.
Important Dates
The last earnings date was Tuesday, May 12, 2026, after market close.
| Earnings Date | May 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
CYCN has 4.23 million shares outstanding. The number of shares has increased by 41.83% in one year.
| Current Share Class | 4.23M |
| Shares Outstanding | 4.23M |
| Shares Change (YoY) | +41.83% |
| Shares Change (QoQ) | +10.34% |
| Owned by Insiders (%) | 17.41% |
| Owned by Institutions (%) | 33.63% |
| Float | 3.49M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 6.64 |
| Forward PS | n/a |
| PB Ratio | 1.95 |
| P/TBV Ratio | 1.95 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 5.22 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.80
| Current Ratio | 1.80 |
| Quick Ratio | 1.65 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -67.77% and return on invested capital (ROIC) is -53.99%.
| Return on Equity (ROE) | -67.77% |
| Return on Assets (ROA) | -45.81% |
| Return on Invested Capital (ROIC) | -53.99% |
| Return on Capital Employed (ROCE) | -99.03% |
| Weighted Average Cost of Capital (WACC) | 14.19% |
| Revenue Per Employee | $1.99M |
| Profits Per Employee | -$5.28M |
| Employee Count | 1 |
| Asset Turnover | 0.22 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -3.40% in the last 52 weeks. The beta is 1.81, so CYCN's price volatility has been higher than the market average.
| Beta (5Y) | 1.81 |
| 52-Week Price Change | -3.40% |
| 50-Day Moving Average | 2.61 |
| 200-Day Moving Average | 2.07 |
| Relative Strength Index (RSI) | 53.06 |
| Average Volume (20 Days) | 120,047 |
Short Selling Information
The latest short interest is 56,618, so 1.34% of the outstanding shares have been sold short.
| Short Interest | 56,618 |
| Short Previous Month | 267,352 |
| Short % of Shares Out | 1.34% |
| Short % of Float | 1.62% |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, CYCN had revenue of $1.99 million and -$5.28 million in losses. Loss per share was -$1.47.
| Revenue | 1.99M |
| Gross Profit | 1.03M |
| Operating Income | -6.73M |
| Pretax Income | -5.28M |
| Net Income | -5.28M |
| EBITDA | n/a |
| EBIT | -6.73M |
| Loss Per Share | -$1.47 |
Full Income StatementBalance Sheet
The company has $2.82 million in cash and n/a in debt, with a net cash position of $2.82 million or $0.67 per share.
| Cash & Cash Equivalents | 2.82M |
| Total Debt | n/a |
| Net Cash | 2.82M |
| Net Cash Per Share | $0.67 |
| Equity (Book Value) | 6.79M |
| Book Value Per Share | 1.60 |
| Working Capital | 1.38M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$3.52 million and capital expenditures -$66,000, giving a free cash flow of -$3.59 million.
| Operating Cash Flow | -3.52M |
| Capital Expenditures | -66,000 |
| Depreciation & Amortization | n/a |
| Net Borrowing | n/a |
| Free Cash Flow | -3.59M |
| FCF Per Share | -$0.85 |
Full Cash Flow StatementMargins
Gross margin is 51.88%, with operating and profit margins of -337.43% and -264.73%.
| Gross Margin | 51.88% |
| Operating Margin | -337.43% |
| Pretax Margin | -264.73% |
| Profit Margin | -264.73% |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
